34 Participants Needed

AHCC Capsules for Head and Neck Cancer

CF
Uo
Overseen ByUniversity of California Irvine Medical
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Do I need to stop taking my current medications to join the trial?

The trial does not specify if you need to stop taking your current medications, but you cannot be on immunosuppressive medication within 7 days before joining, except for certain low-dose steroids and specific premedications.

How is the AHCC treatment different from other treatments for head and neck cancer?

AHCC (Active Hexose Correlated Compound) is unique because it is a natural supplement derived from mushrooms, which may support the immune system, unlike traditional chemotherapy drugs that directly target cancer cells. This makes it a novel approach as it potentially enhances the body's natural defenses rather than directly attacking the cancer.12345

What is the purpose of this trial?

This is a phase 2, single-arm, open-label clinical trial determining safety and tolerability of AHCC in subjects with HPV-positive patients with Head and Neck Squamous Cell Carcinoma. These are subjects who have undergone surgery or will be undergoing surgery.

Research Team

RN

Rupali Nabar

Principal Investigator

Chao Family Comprehensive Cancer Center

Eligibility Criteria

Adults aged 18-79 with HPV-positive Head and Neck Squamous Cell Carcinoma (HNSCC) who've had or will have surgery. They must be at high risk for disease recurrence, not pregnant, willing to use contraception, and free from serious infections, autoimmune diseases treated within the last 2 years, organ transplants, certain heart conditions, HIV with detectable viral load or history of specific diseases.

Inclusion Criteria

I had surgery at least 4 weeks ago.
For patients that have completed surgery, has a high risk disease defined as: Positive Margins and/or Extra Nodal Extension (ENE), No evidence of distant disease based on baseline imaging done within 28 days prior to registration, Has an ECOG Performance Status 0-1, Has the ability to understand and the willingness to sign a written informed consent document, All females of childbearing potential must have a blood test or urine study within 14 days prior to registration negative for pregnancy, Women of childbearing potential and sexually active males must not conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse while on study treatment, and continue for 120 days after the last dose of study treatment, Has adequate organ and marrow function as defined below, based on clinical laboratory assessments obtained ≤ 28 days prior to registration
My throat cancer is caused by HPV.

Exclusion Criteria

I am not currently being treated for an infection.
Known psychiatric or substance abuse disorder that would interfere with the participant's ability to complete study assessments or to adhere to protocol requirements
I have not taken immunosuppressive medication in the last 7 days.
See 8 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive AHCC in combination with standard of care treatment for HPV-positive Head and Neck Squamous Cell Carcinoma

24 cycles (each cycle is 28 days)

Follow-up

Participants are monitored for safety, tolerability, and changes in HPV DNA as a marker of tumor response or recurrence

5 years

Treatment Details

Interventions

  • AHCC
Trial Overview The trial is testing AHCC® capsules' safety and tolerability in HPV-positive HNSCC patients post-surgery. It's a phase 2 study where all participants receive the same treatment without a comparison group.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: AHCCExperimental Treatment1 Intervention
Oral Drug

AHCC is already approved in Japan, United States for the following indications:

🇯🇵
Approved in Japan as AHCC for:
  • General health maintenance
  • Immune support
  • Complementary therapy for cancer patients
🇺🇸
Approved in United States as AHCC for:
  • Dietary supplement for immune support
  • Complementary therapy for cancer patients

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, Irvine

Lead Sponsor

Trials
580
Recruited
4,943,000+

Findings from Research

Paclitaxel was found to be more effective than carboplatin in inducing cell death (apoptosis) and inhibiting growth of head and neck squamous cell carcinoma (HNSCC) cells, with its action linked to increased cyclin B1/CDC2 activity and prolonged mitotic arrest.
Combining paclitaxel and carboplatin, either simultaneously or sequentially, resulted in greater inhibition of cell growth compared to using either drug alone, highlighting the potential for enhanced therapeutic strategies in treating HNSCC.
Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: implications for therapeutic strategies.Coleman, SC., Stewart, ZA., Day, TA., et al.[2019]
Higher T and N stages in head and neck cancer are associated with lower rates of complete local control and survival, highlighting the need for improved treatment strategies.
Combined-modality treatments, such as induction chemotherapy followed by radiotherapy, show promise in enhancing survival and preserving organ function compared to aggressive surgery or radiotherapy alone.
Combined modalities in the treatment of head and neck cancers.Aisner, J., Hiponia, D., Conley, B., et al.[2015]

References

Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: implications for therapeutic strategies. [2019]
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. [2021]
Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor. [2018]
Licochalcone-A induces intrinsic and extrinsic apoptosis via ERK1/2 and p38 phosphorylation-mediated TRAIL expression in head and neck squamous carcinoma FaDu cells. [2022]
Combined modalities in the treatment of head and neck cancers. [2015]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security